PATHOLOGIC STAGE IA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for PATHOLOGIC STAGE IA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new PATHOLOGIC STAGE IA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for PATHOLOGIC STAGE IA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo attack on stomach cancer before surgery
Disease control OngoingThis study is testing a new treatment approach for patients with stomach or gastroesophageal cancer that can be surgically removed. It combines two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy and radiation before surgery, aiming to shrink the tumor and help t…
Matched conditions: PATHOLOGIC STAGE IA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Double-Punch immunotherapy trial aims to wipe out tumors before esophageal cancer surgery
Disease control OngoingThis study is testing whether a powerful combination of treatments can shrink or eliminate tumors before surgery for esophageal and gastroesophageal junction cancers. Patients receive standard chemotherapy and radiation alongside an immunotherapy drug (pembrolizumab), followed by…
Matched conditions: PATHOLOGIC STAGE IA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC